236 related articles for article (PubMed ID: 35996066)
21. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
[TBL] [Abstract][Full Text] [Related]
22. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
23. The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.
Van den Nest M; Glechner A; Gold M; Gartlehner G
Syst Rev; 2019 Dec; 8(1):321. PubMed ID: 31829250
[TBL] [Abstract][Full Text] [Related]
24. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer.
Sussell JA; Roth JA; Meyer CS; Fung A; Hansen SA
Adv Ther; 2022 Mar; 39(3):1375-1392. PubMed ID: 35094298
[TBL] [Abstract][Full Text] [Related]
26. Home-Based Subcutaneous Infusion of Immunoglobulin for Primary and Secondary Immunodeficiencies: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2017; 17(16):1-86. PubMed ID: 31210833
[TBL] [Abstract][Full Text] [Related]
27. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):743-756. PubMed ID: 34003067
[TBL] [Abstract][Full Text] [Related]
28. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.
Anderson KC; Landgren O; Arend RC; Chou J; Jacobs IA
Future Oncol; 2019 Oct; 15(28):3267-3281. PubMed ID: 31394933
[TBL] [Abstract][Full Text] [Related]
29. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
De Cock E; Pivot X; Hauser N; Verma S; Kritikou P; Millar D; Knoop A
Cancer Med; 2016 Mar; 5(3):389-97. PubMed ID: 26806010
[TBL] [Abstract][Full Text] [Related]
30. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S; Collins GP; Samanta K
J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
[TBL] [Abstract][Full Text] [Related]
31. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
Shpilberg O; Jackisch C
Br J Cancer; 2013 Sep; 109(6):1556-61. PubMed ID: 24002601
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy de-escalation using an
Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
[TBL] [Abstract][Full Text] [Related]
33. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
34. Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma.
Monga N; Garside J; Davids MS; Tam C; Ward K; Fotheringham I; O'Donovan P; Parisi L; Tapprich C
Pharmacoecon Open; 2021 Jun; 5(2):175-186. PubMed ID: 32996067
[TBL] [Abstract][Full Text] [Related]
35. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.
Harvey MJ; Zhong Y; Morris E; Beverage JN; Epstein RS; Chawla AJ
PLoS One; 2022; 17(1):e0261336. PubMed ID: 35073335
[TBL] [Abstract][Full Text] [Related]
36. Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.
Drill E; Qiu A; Shapouri S; To TM; Ravelo A; Schade J; Dawson K; Matasar M
Oncology (Williston Park); 2021 Dec; 35(12):804-811. PubMed ID: 35089000
[TBL] [Abstract][Full Text] [Related]
37. Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain.
Alonso Torres AM; Arévalo Bernabé AG; Becerril Ríos N; Hellín Gil MF; Martínez Sesmero JM; Meca Lallana V; Ramió-Torrentà L; Rodríguez-Antigüedad A; Gómez Maldonado L; Triana Junco I; Gómez-Barrera M; Espinoza Cámac N; Oyagüez I
Pharmacoecon Open; 2023 May; 7(3):431-441. PubMed ID: 36802327
[TBL] [Abstract][Full Text] [Related]
38. Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Squires H; Pandor A; Thokala P; Stevens JW; Kaltenthaler E; Clowes M; Coleman R; Wyld L
Pharmacoeconomics; 2018 Jan; 36(1):29-38. PubMed ID: 28770452
[TBL] [Abstract][Full Text] [Related]
39. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.
Gao JJ; Osgood CL; Gong Y; Zhang H; Bloomquist EW; Jiang X; Qiu J; Yu J; Song P; Rahman NA; Chiu HJ; Ricks TK; Rizvi F; Hou S; Wilson W; Abukhdeir AM; Seidman J; Ghosh S; Philip R; Pierce WF; Bhatnagar V; Kluetz PG; Pazdur R; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2021 Apr; 27(8):2126-2129. PubMed ID: 33188141
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]